CellSource Co., Ltd. (JP:4880)
:4880
Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥308.00 - ¥750.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥6.29B
Enterprise Value¥2.31B
Total Cash (Recent Filing)¥4.71B
Total Debt (Recent Filing)¥56.72M
Price to Earnings (P/E)70.0
Beta0.85
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)0.53
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.83
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5
Revenue Forecast (FY)¥3.70B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow financial leverage provides durable resilience: minimal debt reduces default and refinancing risk, preserves capacity to fund R&D or strategic partnerships from internal resources, and gives management flexibility to invest through industry cycles without immediate external financing.
Consistent Positive Cash GenerationOngoing positive operating and free cash flow supports self-funding of operations and product development. Even with volatility, repeated cash generation reduces dilution risk, underpins supply of consumables/services, and strengthens the firm's ability to scale clinical and commercial activities.
Diversified Regenerative-medicine Revenue ModelMultiple revenue streams (cell-processing services, equipment sales, consumables, licensing, and partnerships) create structural resilience: recurring service and consumable demand plus licensing income smooths cash flow and supports steady adoption across clinics and hospitals over the medium term.
Bears Say
Sharply Deteriorated ProfitabilityA collapse in net margin to near break-even materially weakens return on capital and long-term reinvestment capacity. Sustained low profitability undermines the company's ability to fund trials, commercialization, and margin expansion without either cost restructuring or new capital.
Volatile Free Cash Flow And Weakening Cash QualitySharp declines and volatility in free cash flow reduce predictability of funding for R&D and capital expenditures. This increases reliance on external financing or partnership deals, raising execution risk for product rollouts and capacity expansion over the next several quarters.
Inconsistent Revenue GrowthBumpy top-line trends indicate demand or execution variability. Inconsistent revenue complicates capacity planning for processing services and consumables, weakens forecasting, and can magnify margin pressure if fixed costs are not well matched to revenue cycles.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥308.00 and its highest was ¥750.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.29B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Sep 10, 2026 which is in 91 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥1.89 earnings per share for the quarter, beating the consensus estimate of N/A by ¥1.89.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.24%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.89 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.631%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―